TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $220.
TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $220.